Glaukos Corporation Stock News

The

Envestnet Asset Management Inc. lessened its holdings in shares of Glaukos Corp (NYSE:GKOS) by 54.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commis

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...

Jacobi Capital Management LLC acquired a new stake in Glaukos Corp (NYSE:GKOS) during the 2nd quarter, Holdings Channel reports. The fund acquired 1,000 shares of the medical instruments supplier’s

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to

Invesco Ltd. reduced its position in Glaukos Corp (NYSE:GKOS) by 62.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned

Increasing adoption of microkeratome procedures coupled with the rising number of age-related disorders.

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F

Thrivent Financial for Lutherans bought a new stake in Glaukos Corp (NYSE:GKOS) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange C

Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.

Glaukos Corp (NYSE:GKOS) – Stock analysts at Jefferies Financial Group issued their Q2 2020 earnings per share estimates for Glaukos in a research note issued on Monday, June 15th. Jefferies Financi

Jefferies Financial Group initiated coverage on shares of Glaukos (NYSE:GKOS) in a research note released on Monday, BenzingaRatingsTable reports. The brokerage issued a hold rating and a $44.00 price

BNP Paribas Arbitrage SA cut its stake in Glaukos Corp (NYSE:GKOS) by 43.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The instituti

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today an